Drugs / Novolin N
Novolin N
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | NOVOLIN N | — | 1991-07-01 | fda.gov ↗ |
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT00772265 Comparator | Sep 2010 → Mar 2011 | diabetes mellitus | Wockhardt | Completed | No outcome recorded |
| — | NCT01833559 Background | Jun 2012 → May 2021 | gestational diabetes | First Affiliated Hospital, Sun Yat-Sen University | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Novolin N | “Novolin N” NCT01833559 ↗ |
| Known as | Isophane insulin | “Novolin N, Isophane insulin for injection (Recominant Human Insulin)(100IU/ml),cartridges 3.0ml.” NCT00772265 ↗ |
| Known as | Recominant Human Insulin | “Novolin N, Isophane insulin for injection (Recominant Human Insulin)(100IU/ml),cartridges 3.0ml.” NCT00772265 ↗ |
| Modality | Protein / enzyme biologic | “Recominant Human Insulin” NCT00772265 ↗ |
| Route | Subcutaneous | “given Subcutaneously” NCT00772265 ↗ |